Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

L’Oréal S&E

This article was originally published in The Rose Sheet

Executive Summary

Consumer products net sales grew 5.5% like-for-like or 6.4% on a reported basis to $7.48 bil. (€1=$1.25) for the first nine months of the year, French beauty company reports Oct. 12. In the U.S., the Fructis range made further market share gains, while Nutrisse made "great strides forward" and Maybelline brand sales were boosted by SuperStay lipstick and Dream Matte Mousse foundation, firm notes. Luxury cosmetics sales advanced 4.9% like-for-like or 6.5% on a reported basis to $3.37 bil., while professional product sales increased 3.4% like-for-like or 4% as reported to $2 bil. Net sales for the nine months were up 5.6% like-for-like and 8.3% on a reported basis to $14.57 bil...

You may also be interested in...



FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says

The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.

ImmunityBio Will Aim Anktiva At Large Share Of Bladder Cancer Market

Execs Richard Adcock and Patrick Soon-Shiong told Scrip the company sees an addressable US population of about 20,000 and is aiming for ease of physician adoption.

Scrip M&A Podcast: Which Companies Could Be Acquired Next?

The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014282

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel